Epirubicin (Accord)


What it is used for

Epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-Hodgkin’s lymphoma), advanced/ metastatic soft tissue sarcoma, superficial bladder cancer (Tis; Ta). In bladder cancer, Epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage T1 papillary cancers and stage Ta multifocal papillary cancers (grades 2 and 3).


How to take it

The way to take this medicine is: Intravesical.

  • Store at 2 to 8 degrees Celsius
  • Refrigerate
  • Protect from Light
  • Do not Freeze
  • Shelf lifetime is 2 Years.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.


Reporting side effects

You can help ensure medicines are safe by reporting the side effects you experience.

You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems


How to take it

The way to take this medicine is: Intravesical.

  • Store at 2 to 8 degrees Celsius
  • Refrigerate
  • Protect from Light
  • Do not Freeze
  • Shelf lifetime is 2 Years.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.


Pregnant or planning a pregnancy?

For the active ingredient epirubicin

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.


Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.


Visual appearance

Clear red solution in a clear glass vial with white or royal blue flip off seal

0 0 votes
Do you use this medicine? Rate it:
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments